外周T细胞淋巴瘤中guadecitabine(SGI-110)的整合临床与基因组评估
这项II期单臂试验评估了guadecitabine在外周T细胞淋巴瘤(PTCL)患者中的疗效与安全性,主要终点为总缓解率和安全性。20例以复发/难治为主的患者中,总缓解率为40%(完全缓解10%),最常见3-4级不良事件为中性粒细胞减少和血小板减少。中位随访10个月时,中位无进展生存期和总生存期分别为2.9个月和10.4个月。
要点
- 20例PTCL患者中总缓解率40%,完全缓解率10%。
- RHOAG17V突变与无进展生存期改善相关:中位5.47 vs 1.35个月(Wilcoxon P=0.02,Log-Rank P=0.06)。
- SETD2缺失使细胞对HMA敏感,而TET2缺失未产生相同效果。
核心结论
- Guadecitabine在PTCL中显示出可接受的ORR和毒性特征;decitabine类似物可能为未来联合靶向组蛋白甲基转移酶的治疗方案提供骨架。
研究设计与样本
- II期单臂试验,PTCL患者接受guadecitabine第1-5天给药,28天为一周期。
- 主要终点为总缓解率(ORR)和安全性;转化子研究包括游离血浆DNA测序和表观遗传靶向CRISPR/Cas9文库功能基因组筛查。
- 共纳入20例患者,以复发/难治为主。
主要发现
- 总缓解率为40%,其中完全缓解占10%。
- 最常见的3-4级不良事件为中性粒细胞减少和血小板减少。
- 中位随访10个月时,中位无进展生存期(PFS)为2.9个月,中位总生存期(OS)为10.4个月。
- RHOAG17V突变与PFS改善相关:中位5.47 vs 1.35个月(Wilcoxon P=0.02,Log-Rank P=0.06)。
- 7例携带TP53变异的患者中有4例缓解;SETD2缺失使细胞对HMA敏感,而TET2缺失未产生相同效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes at relapse. Hypomethylating agents (HMA) have an emerging role in PTCL, supported by shared mutations with myelodysplasia (MDS). Response rates to azacitidine in PTCL of follicular helper cell origin are promising. Guadecitabine is a decitabine analogue with efficacy in MDS. In this phase II, single-arm trial, PTCL patients received guadecitabine on days 1-5 of 28-day cycles. Primary end points were overall response rate (ORR) and safety. Translational sub-studies included cell free plasma DNA sequencing and functional genomic screening using an epigenetically-targeted CRISPR/Cas9 library to identify response predictors. Among 20 predominantly relapsed/refractory patients, the ORR was 40% (10% complete responses). Most frequent grade 3-4 adverse events were neutropenia and thrombocytopenia. At 10 months median follow-up, median progression free survival (PFS) and overall survival (OS) were 2.9 and 10.4 months respectively. RHOAG17V mutations associated with improved PFS (median 5.47 vs. 1.35 months; Wilcoxon p = 0.02, Log-Rank p = 0.06). 4/7 patients with TP53 variants responded. Deletion of the histone methyltransferase SETD2 sensitised to HMA but TET2 deletion did not. Guadecitabine conveyed an acceptable ORR and toxicity profile; decitabine analogues may provide a backbone for future combinatorial regimens co-targeting histone methyltransferases.
引用
- Wong J, Gruber E, Maher B, et al. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia. 2022. PMID: 35459873. doi:10.1038/s41375-022-01571-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。